Wrapping up Q4 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including Insulet ...

Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of ...

Abbott Laboratories (NYSE:ABT) reported new FreeDM2 trial results on its FreeStyle Libre continuous glucose monitoring system ...

If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that price might actually represent for you. The stock has been under pressure ...

Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued paten ...

International Diabetes Federation” (IDF) President-elect, Dr Niti Pall, currently on India visit, called on Union Minister Dr ...

On March 12, 2026, Insulet initiated a voluntary medical device correction in the U.S. for specific lots of its Omnipod 5 Pods after product monitoring identified a manufacturing issue that can cause ...

MiniMed (MNMD) stock rebounds as the post-IPO quiet period ends, generating multiple bullish views from Wall Street analysts.

In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott ...

Family members line up in government offices in hopes of securing assistance and temporary relief, in the absence of a more ...

Sensi launches Collections, new curated services to address parts of wellness experience often forgotten.

Discover how MiniMed's full-stack diabetes technology and global reach post-IPO could transform a rapidly growing $18B ...